Daunorubicin (Synonyms: Daunomycin; RP 13057; Rubidomycin)

Cat. No.: HY-13062A: Data Sheet Handling Instructions Technical Support

Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Daunorubicin hydrochloride) usually boasts enhanced water solubility and stability.

For research use only. We do not sell to patients.

Daunorubicin Chemical Structure

CAS No. : 20830-81-3

Size	Stock
5 mg	Get quote	Estimated Time of Arrival: April 10
10 mg	Get quote	Estimated Time of Arrival: April 10
25 mg	Get quote	Estimated Time of Arrival: April 10

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Daunorubicin:

29 Publications Citing Use of MCE Daunorubicin

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II

View All ADC Cytotoxin Isoform Specific Products:

View All Isoforms

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[2]

Topoisomerase II

Daunorubicins/Doxorubicins

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	0.3 μM Compound: Daunorubicin	Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay	[PMID: 30654237]
4T1	IC₅₀	40.8 nM Compound: Dau	Cytostatic activity against mouse 4T1 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against mouse 4T1 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
A2058	IC₅₀	33.3 nM Compound: Dau	Cytostatic activity against human A2058 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human A2058 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
A2780 ADR	GI₅₀	0.01 μM Compound: Daunorubicin	Inhibition of daunorubicin sensitive human A2780 ADR cells expressing P-gp measured for 72 hrs by MTT assay Inhibition of daunorubicin sensitive human A2780 ADR cells expressing P-gp measured for 72 hrs by MTT assay	[PMID: 29016119]
A2780 ADR	GI₅₀	0.575 μM Compound: Daunorubicin	Inhibition of cell growth in Daunorubicin resistant human A2780 ADR cells expressing P-gp measured for 72 hrs by MTT assay Inhibition of cell growth in Daunorubicin resistant human A2780 ADR cells expressing P-gp measured for 72 hrs by MTT assay	[PMID: 29016119]
A549	GI₅₀	0.08 μM Compound: daunorubicin	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 19968258]
A549	IC₅₀	0.08 μM Compound: Daunorubicin	Antiproliferative activity against human A549 cells by XTT assay Antiproliferative activity against human A549 cells by XTT assay	[PMID: 25467291]
A549	IC₅₀	0.15 μM Compound: Daunorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 30902399]
A549	IC₅₀	0.51 μM Compound: Daunorubicin	Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
A549	IC₅₀	0.53 μM Compound: Daunorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31431363]
A549	IC₅₀	68.2 nM Compound: Dau	Cytostatic activity against human A549 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human A549 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
ACHN	IC₅₀	63 nM Compound: daunorubicin	Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay	[PMID: 17286393]
B16	EC₅₀	0.16 μM Compound: daunomycin	Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in B16 mouse melanoma cells using MTS assay. Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in B16 mouse melanoma cells using MTS assay.	[PMID: 11020285]
B16	IC₅₀	8.9 nM Compound: Dau	Cytostatic activity against mouse B16 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against mouse B16 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
BHK-21	IC₅₀	0.09 μM Compound: Daunorubicin	Cytotoxicity against BHK21 cells after 72 hrs by MTT assay Cytotoxicity against BHK21 cells after 72 hrs by MTT assay	[PMID: 30654237]
COLO 205	IC₅₀	0.5 μg/mL Compound: daunorubicin	Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay	[PMID: 19606850]
CT26.WT	IC₅₀	0.42 μM Compound: Daunorubicin	Cytotoxicity against mouse CT26.WT cells after 72 hrs by MTT assay Cytotoxicity against mouse CT26.WT cells after 72 hrs by MTT assay	[PMID: 30654237]
CT26.WT	IC₅₀	126 nM Compound: Dau	Cytostatic activity against mouse CT26.WT cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against mouse CT26.WT cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
DA-3 cell line	IC₅₀	1.9 μM Compound: DNR	Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay	[PMID: 24900668]
Detroit 551	GI₅₀	1.77 μM Compound: DAR	Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay	[PMID: 20591678]
DU-145	IC₅₀	0.09 μM Compound: DAU	Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay	[PMID: 22260166]
DU-145	IC₅₀	24.5 nM Compound: Dau	Cytostatic activity against human DU145 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human DU145 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
H69AR	IC₅₀	> 1000 nM Compound: daunorubicin	Antiproliferative activity against drug resistant H69AR cell line expressing MRP1 by Alamar Blue assay Antiproliferative activity against drug resistant H69AR cell line expressing MRP1 by Alamar Blue assay	[PMID: 17286393]
H69AR	GI₅₀	0.361 μM Compound: Daunorubicin	Inhibition of daunorubicin sensitive human NCI-H69AR cells expressing MRP1 measured for 72 hrs by MTT assay Inhibition of daunorubicin sensitive human NCI-H69AR cells expressing MRP1 measured for 72 hrs by MTT assay	[PMID: 29016119]
H69AR	GI₅₀	3.84 μM Compound: Daunorubicin	Inhibition of cell growth in Daunorubicin resistant human NCI-H69AR cells expressing MRP1 measured for 72 hrs by MTT assay Inhibition of cell growth in Daunorubicin resistant human NCI-H69AR cells expressing MRP1 measured for 72 hrs by MTT assay	[PMID: 29016119]
HCT-116	IC₅₀	0.21 μM Compound: Daunorubicin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31431363]
HCT-116	IC₅₀	127.1 nM Compound: Dau	Cytostatic activity against human HCT116 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human HCT116 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
HCT-15	IC₅₀	> 400 nM Compound: daunorubicin	Antiproliferative activity against drug resistant HCT15 cell line expressing MDR1 by Alamar Blue assay Antiproliferative activity against drug resistant HCT15 cell line expressing MDR1 by Alamar Blue assay	[PMID: 17286393]
HEK293	IC₅₀	1.2 μM Compound: Daunonthicin	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 24 hrs by alamar blue assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 24 hrs by alamar blue assay	[PMID: 36449385]
HEK293	IC₅₀	11.17 μM Compound: Daunorubicin	Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
HEK293	IC₅₀	11.17 μM Compound: Daunorubicin	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31431363]
HEK293	IC₅₀	12.55 μM Compound: Daunorubicin	Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar blue assay Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar blue assay	[PMID: 29190092]
HEK293	IC₅₀	12.55 μM Compound: Daunorubicin	Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar Blue assay Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar Blue assay	[PMID: 26937828]
HeLa	IC₅₀	2.96 μM Compound: daunomycin	Cytotoxicity against human HeLa3 cell line by MTT assay Cytotoxicity against human HeLa3 cell line by MTT assay	[PMID: 16942037]
HepG2	IC₅₀	0.7 μM Compound: Dauno	Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay	[PMID: 21094049]
HepG2	IC₅₀	21.3 nM Compound: Dau	Cytostatic activity against human HepG2 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human HepG2 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
HL-60	GI₅₀	0.1 μM Compound: Daunorubicin	Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis	[PMID: 25874335]
HL-60	IC₅₀	15 nM Compound: DAU	Antiproliferative activity against human HL-60 cells after 72 hrs by XTT assay Antiproliferative activity against human HL-60 cells after 72 hrs by XTT assay	[PMID: 33750129]
HT-29	GI₅₀	0.07 μM Compound: daunorubicin	Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay	[PMID: 19968258]
HT-29	IC₅₀	0.2 μM Compound: Dau, daunomycin	Cytostatic activity against human HT-29 cells after 4 days by MTT assay Cytostatic activity against human HT-29 cells after 4 days by MTT assay	[PMID: 22480495]
HT-29	IC₅₀	0.4 μM Compound: Dauno	Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay	[PMID: 21094049]
HT-29	IC₅₀	133 nM Compound: Daunomycin	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 2778449]
HT-29	IC₅₀	202.9 nM Compound: Dau	Cytostatic activity against human HT-29 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human HT-29 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
Jurkat	IC₅₀	82.6 nM Compound: Daunorubicin	Cytotoxicity against Jurkat T lymphocytes by MTT assay Cytotoxicity against Jurkat T lymphocytes by MTT assay	[PMID: 16366602]
K562	IC₅₀	> 5 μM Compound: DNR	Cytotoxicity against Dox-resistant K562 cells by MTS Cytotoxicity against Dox-resistant K562 cells by MTS	[PMID: 16451059]
K562	GI₅₀	0.0074 μM Compound: DAR	Cytotoxicity against human K562 cells after 72 hrs by XTT assay Cytotoxicity against human K562 cells after 72 hrs by XTT assay	[PMID: 20591678]
K562	IC₅₀	0.45 μg/mL Compound: daunorubicin	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 19606850]
K562	IC₅₀	1.49 μg/mL Compound: Daunorubicin	Cytotoxicity against human K562 cells after 6 hrs by MTT assay Cytotoxicity against human K562 cells after 6 hrs by MTT assay	[PMID: 21493075]
K562	IC₅₀	15 nM Compound: DNR	Cytotoxicity against K562 cells by MTS Cytotoxicity against K562 cells by MTS	[PMID: 16451059]
K562	IC₅₀	15.2 μg/mL Compound: daunorubicin	Cytotoxicity against human doxorubicin-resistant K562 cells after 48 hrs by MTT assay Cytotoxicity against human doxorubicin-resistant K562 cells after 48 hrs by MTT assay	[PMID: 19606850]
K562	IC₅₀	8.5 μg/mL Compound: Daunorubicin	Cytotoxicity against human doxorubicin-resistant K562 cells after 6 hrs by MTT assay Cytotoxicity against human doxorubicin-resistant K562 cells after 6 hrs by MTT assay	[PMID: 21493075]
KB	IC₅₀	0.22 μg/mL Compound: daunorubicin	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 19606850]
KB	IC₅₀	0.45 μg/mL Compound: Daunorubicin	Cytotoxicity against human KB cells after 6 hrs by MTT assay Cytotoxicity against human KB cells after 6 hrs by MTT assay	[PMID: 21493075]
KB	IC₅₀	0.64 μM Compound: Daunorubicin	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 20363142]
KB	IC₅₀	2.07 μM Compound: DNR	In vitro cytotoxicity using human epidermoid carcinoma (KB-A1) cells In vitro cytotoxicity using human epidermoid carcinoma (KB-A1) cells	10.1016/0960-894X(96)00457-X
KB	IC₅₀	2.07 μM Compound: Daunomycin (DNR)	In vitro cytotoxic activity was evaluated using the KB-3-1 resistant to adriamycin (ADR) subline KB-A1 In vitro cytotoxic activity was evaluated using the KB-3-1 resistant to adriamycin (ADR) subline KB-A1	[PMID: 12443763]
KB 3-1	IC₅₀	0.007 μM Compound: DNR	In vitro cytotoxicity using human epidermoid carcinoma (KB-3-1) cells In vitro cytotoxicity using human epidermoid carcinoma (KB-3-1) cells	10.1016/0960-894X(96)00457-X
KB 3-1	IC₅₀	0.007 μM Compound: Daunomycin (DNR)	In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1 In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1	[PMID: 12443763]
L1210	IC₅₀	0.033 μM Compound: DNR	In vitro cytotoxicity using murine leukemia L1210 cells from american type culture collection. In vitro cytotoxicity using murine leukemia L1210 cells from american type culture collection.	10.1016/0960-894X(96)00457-X
L1210	IC₅₀	0.04 μM Compound: Daunomycin (DNR)	In vitro cytotoxic activity was evaluated using the murine leukemia L1210 cell line In vitro cytotoxic activity was evaluated using the murine leukemia L1210 cell line	[PMID: 12443763]
L1210	ED₅₀	0.3 μM Compound: Daunomycin	Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis	[PMID: 176359]
L1210	ED₅₀	0.3 μM Compound: Daunomycin	Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis	[PMID: 176359]
L1210	ED₅₀	0.33 μM Compound: 2	Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells. Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells.	[PMID: 7086816]
L1210	ED₅₀	0.66 μM Compound: 2	Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells	[PMID: 7086816]
L5178Y	IC₅₀	0.3 μM Compound: liposomal daunorubicin, DaunoXome	Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay	[PMID: 23199479]
L5178Y	IC₅₀	0.73 μM Compound: Daunorubicin	Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay	[PMID: 23199479]
L5178Y	IC₅₀	2.32 μM Compound: liposomal daunorubicin, DaunoXome	Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay	[PMID: 23199479]
L5178Y	IC₅₀	7.73 μM Compound: Daunorubicin	Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay	[PMID: 23199479]
LNCaP	IC₅₀	0.1 μM Compound: Dau, daunomycin	Cytostatic activity against human LNCAP cells after 4 days by MTT assay Cytostatic activity against human LNCAP cells after 4 days by MTT assay	[PMID: 22480495]
MCF7	IC₅₀	0.033 μg/mL Compound: Daunorubicin	Cytotoxicity against human MCF7 cells after 6 hrs by MTT assay Cytotoxicity against human MCF7 cells after 6 hrs by MTT assay	[PMID: 21493075]
MCF7	IC₅₀	0.33 μg/mL Compound: daunorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 19606850]
MCF7	IC₅₀	0.4 μM Compound: Dau, daunomycin	Cytostatic activity against human MCF7 cells after 4 days by MTT assay Cytostatic activity against human MCF7 cells after 4 days by MTT assay	[PMID: 22480495]
MCF7	IC₅₀	0.5 μg/mL Compound: Daunorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21109433]
MCF7	IC₅₀	0.56 μM Compound: Daunorubicin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31431363]
MCF7	IC₅₀	0.65 μM Compound: Daunorubicin	Antiproliferative activity against human MCF7 cells by XTT assay Antiproliferative activity against human MCF7 cells by XTT assay	[PMID: 25467291]
MCF7	GI₅₀	0.86 μM Compound: DAR	Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay	[PMID: 20591678]
MCF7	IC₅₀	0.95 μM Compound: DAU	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 22260166]
MCF7	IC₅₀	1.44 μM Compound: Daunorubicin	Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
MCF7	IC₅₀	286 nM Compound: Dau	Cytostatic activity against human MCF7 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human MCF7 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
MCF7	IC₅₀	33.9 μM Compound: DNR	Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay	[PMID: 24900668]
MCF7	IC₅₀	5.5 μM Compound: Dauno	Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay	[PMID: 21094049]
MDA-MB-231	GI₅₀	0.02 μM Compound: daunorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 19968258]
MDA-MB-231	IC₅₀	0.091 μM Compound: Daunorubicin	Antiproliferative activity against human MDA-MB-231 cells by XTT assay Antiproliferative activity against human MDA-MB-231 cells by XTT assay	[PMID: 25467291]
MDA-MB-231	IC₅₀	52.9 nM Compound: Dau	Cytostatic activity against human MDA-MB-231 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human MDA-MB-231 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
MDA-MB-435	IC₅₀	129 nM Compound: Daunorubicin	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	79 nM Compound: Daunorubicin	Antiproliferative activity against MDA435/LCC6 cells by ELISA Antiproliferative activity against MDA435/LCC6 cells by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	977 nM Compound: Daunorubicin	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA	[PMID: 17154505]
MES-SA	IC₅₀	0.021 μM Compound: DNR	The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay. The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay.	[PMID: 10698449]
MES-SA	IC₅₀	0.07 μM Compound: Daunomycin (DNR)	In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA	[PMID: 12443763]
MES-SA	IC₅₀	20 nM Compound: daunorubicin	Antiproliferative activity against drug sensitive Messa cell line by Alamar Blue assay Antiproliferative activity against drug sensitive Messa cell line by Alamar Blue assay	[PMID: 17286393]
MES-SA	IC₅₀	3 μM Compound: Daunomycin (DNR)	In vitro cytotoxic activity was evaluated using the MES-SA multidrug-resistant subline MES-SA/Dx5 In vitro cytotoxic activity was evaluated using the MES-SA multidrug-resistant subline MES-SA/Dx5	[PMID: 12443763]
MES-SA/Dx5	IC₅₀	> 400 nM Compound: daunorubicin	Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay	[PMID: 17286393]
MES-SA/Dx5	IC₅₀	0.014 μM Compound: DNR	The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay. The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay.	[PMID: 10698449]
MES-SA/Dx5	IC₅₀	2 μM Compound: DNR	The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay. The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay.	[PMID: 10698449]
MRC5	IC₅₀	0.078 μM Compound: Daunorubicin	Antiproliferative activity against human MRC5 cells by XTT assay Antiproliferative activity against human MRC5 cells by XTT assay	[PMID: 25467291]
MRC5	IC₅₀	254.7 nM Compound: Dau	Cytostatic activity against human MRC5 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human MRC5 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
NCI/ADR-RES	IC₅₀	51.62 μM Compound: Daunorubicin	Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay	[PMID: 33725657]
NCI/ADR-RES	IC₅₀	7.12 μM Compound: Daunomycin	Growth inhibition of human MCF7/ADR cells after 48 hrs by SRB assay Growth inhibition of human MCF7/ADR cells after 48 hrs by SRB assay	[PMID: 28246041]
NCI-H1299	IC₅₀	0.096 μM Compound: Daunorubicin	Antiproliferative activity against human H1299 cells by XTT assay Antiproliferative activity against human H1299 cells by XTT assay	[PMID: 25467291]
NCI-H1650	IC₅₀	47.5 nM Compound: Dau	Cytostatic activity against human NCI-H1650 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human NCI-H1650 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
NCI-H1975	IC₅₀	13.3 nM Compound: Dau	Cytostatic activity against human NCI-H1975 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human NCI-H1975 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
NCI-H460	GI₅₀	0.38 μM Compound: DAR	Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay	[PMID: 20591678]
NCI-H69	IC₅₀	100 nM Compound: daunorubicin	Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay	[PMID: 17286393]
NIH3T3	IC₅₀	0.044 μM Compound: Dounorubicin	Intrinsic cytotoxicity against wild type mouse NIH/3T3 cells after 72 hrs by MTT assay Intrinsic cytotoxicity against wild type mouse NIH/3T3 cells after 72 hrs by MTT assay	[PMID: 18954040]
NIH3T3	IC₅₀	1.01 μM Compound: Dounorubicin	Intrinsic cytotoxicity against mouse NIH/3T3 cells overexpressing MDR1 after 72 hrs by MTT assay Intrinsic cytotoxicity against mouse NIH/3T3 cells overexpressing MDR1 after 72 hrs by MTT assay	[PMID: 18954040]
NIH3T3	IC₅₀	1.8 μM Compound: Dauno	Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay	[PMID: 21094049]
OVCAR-3	IC₅₀	472.9 nM Compound: Dau	Cytostatic activity against human OVCAR3 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human OVCAR3 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
P388	IC₅₀	25 nM Compound: Daunorubicin	Antiproliferative activity against P388 cells by ELISA Antiproliferative activity against P388 cells by ELISA	[PMID: 17154505]
P388	IC₅₀	28 nM Compound: Daunomycin	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 2778449]
P388/ADR	IC₅₀	106 nM Compound: Daunorubicin	Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	[PMID: 17154505]
P388/ADR	IC₅₀	2111 nM Compound: Daunorubicin	Antiproliferative activity against adriamycin resistant P388 cells by ELISA Antiproliferative activity against adriamycin resistant P388 cells by ELISA	[PMID: 17154505]
P388/ADR	IC₅₀	40 nM Compound: Daunorubicin	Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM verapamil by ELISA Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM verapamil by ELISA	[PMID: 17154505]
PANC-1	IC₅₀	466.7 nM Compound: Dau	Cytostatic activity against human PANC1 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human PANC1 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
PC-3	IC₅₀	26 nM Compound: Dau	Cytostatic activity against human PC3 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human PC3 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
RD	IC₅₀	2.45 μM Compound: Daunorubicin	Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
RD	IC₅₀	2.45 μM Compound: Daunorubicin	Antiproliferative activity against human RD cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human RD cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31431363]
SF-268	GI₅₀	0.6 μM Compound: DAR	Cytotoxicity against human SF268 cells after 72 hrs by XTT assay Cytotoxicity against human SF268 cells after 72 hrs by XTT assay	[PMID: 20591678]
SK-MES-1	IC₅₀	0.17 μM Compound: DAU	Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay	[PMID: 22260166]
SK-OV-3	IC₅₀	20.6 μM Compound: DNR	Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay	[PMID: 24900668]
THP-1	IC₅₀	26.9 μM Compound: DNM	Cytotoxicity against PMA-stimulated human THP1 cells after 72 hrs by MTT assay Cytotoxicity against PMA-stimulated human THP1 cells after 72 hrs by MTT assay	[PMID: 22939695]
U-87MG ATCC	IC₅₀	27.9 nM Compound: Dau	Cytostatic activity against human U87 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human U87 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]
Vero	IC₅₀	2.5 μM Compound: Dauno	Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay	[PMID: 21094049]
WiDr	IC₅₀	240.1 nM Compound: Dau	Cytostatic activity against human WiDr cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay Cytostatic activity against human WiDr cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	[PMID: 31100648]

In Vitro

Daunorubicin (0-256 μg/mL, 30 min) inhibits DNA and RNA synthesis in sensitive and resistant Ehrlich ascites tumor cells^[2].
Daunorubicin (7 nM-1.9 μM, 72 h) shows chemosensitivity in Molt-4 cells and L3.6 cells^[3]^[4].
Daunorubicin (0.4 μM, 48 h) induces apoptotic and necrosis in L3.6 cells^[4].
Daunorubicin (0.4 μM, 120 min) induces ROS generation in L3.6 cells^[4].
Daunorubicin (2 μM, 24 h) induces autophagy in K562 cells (myeloid cell line)^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]^[4]

Cell Line:	Molt-4 cells (a human T-lymphoblastic leukemia cell line), L3.6 cells (metastatic human pancreatic cell line)
Concentration:	7 nM-1.9 μM
Incubation Time:	72 h
Result:	Inhibited cell viability with IC₅₀ values of 40 nM (Molt-4) and 400 nM (L3.6).

Apoptosis Analysis^[4]

Cell Line:	L3.6 cells
Concentration:	0.4 μM
Incubation Time:	24 h, 48 h
Result:	Induced necrosis without apoptosis at 24 h, induced both an apoptotic and extensive necrotic response at 48 h.

Western Blot Analysis^[6]

Cell Line:	K562 cells
Concentration:	2 μM
Incubation Time:	24 h
Result:	Enabled the switch of LC3-I into LC3-II, accompanied with a significant increased expression level of LC3.

In Vivo

Daunorubicin (intravenous injection, 3 mg/kg, three times at 48 h intervals.) produces cardiotoxicity and nephrotoxicity in rats^[5].
Daunorubicin (intraperitoneal injection, 10 mg/kg) induces sister chromatid exchanges in mice^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats^[5]
Dosage:	3 mg/kg
Administration:	Intravenous injection, three times at 48 h intervals.
Result:	Caused a significant increase in MDA (malondialdehyde) level in renal tissue, accompanied by a significant reduction in total GPx activity. Increased urinary protein excretion, serum creatinine, and BUN level.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00003190	National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Untreated Adult Acute Myeloid Leukemia	January 1998	Phase 3
NCT00005945	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	June 2000	Phase 3
NCT00022126	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	November 2002	Phase 2
NCT03507842	Asan Medical Center	Acute Myeloid Leukemia	March 1, 2018	Phase 3
NCT00764907	University Hospital, Motol\|National Cancer Institute (NCI)	Leukemia	November 2002	Phase 3
NCT00003437	Medical Research Council\|National Cancer Institute (NCI)	Leukemia	January 1997	Phase 3
NCT00416598	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Acute Myeloid Leukemia With Myelodysplasia-Related Changes\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A\|Untreated Adult Acute Myeloid Leukemia	November 15, 2006	Phase 2
NCT03724084	National Cancer Institute (NCI)	Acute Myeloid Leukemia	January 25, 2019	Phase 1\|Phase 2
NCT00494897	PETHEMA Foundation	Acute Lymphoblastic Leukemia	June 1996	Phase 4
NCT01999413	French Innovative Leukemia Organisation\|Fresenius Kabi	Acute Myeloid Leukemia (AML)	November 2013	Phase 2
NCT03444649	Insel Gruppe AG, University Hospital Bern	AML	September 2018	Phase 1
NCT00002658	Medical Research Council\|National Cancer Institute (NCI)	Leukemia\|Neutropenia	January 1994	Phase 3
NCT00061945	National Cancer Institute (NCI)	Acute Undifferentiated Leukemia\|B-cell Adult Acute Lymphoblastic Leukemia\|B-cell Childhood Acute Lymphoblastic Leukemia\|L1 Adult Acute Lymphoblastic Leukemia\|L1 Childhood Acute Lymphoblastic Leukemia\|L2 Adult Acute Lymphoblastic Leukemia\|L2 Childhood Acute Lymphoblastic Leukemia\|Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia\|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia\|Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia\|T-cell Adult Acute Lymphoblastic Leukemia\|T-cell Childhood Acute Lymphoblastic Leukemia\|Untreated Adult Acute Lymphoblastic Leukemia\|Untreated Childhood Acute Lymphoblastic Leukemia	June 2003	Phase 1\|Phase 2
NCT03643276	Martin Schrappe\|Deutsche Krebshilfe e.V., Bonn (Germany)\|University Hospital Schleswig-Holstein	Acute Lymphoblastic Leukemia, Pediatric	July 15, 2018	Phase 3
NCT02660762	Sun Yat-sen University	Leukaemia,Lymphoblastic	January 2016	Phase 2
NCT00742625	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Untreated Adult Acute Myeloid Leukemia	September 2008	Phase 1\|Phase 2
NCT02954653	Pfizer	Acute Myeloid Leukemia	November 28, 2016	Phase 1
NCT01920737	Memorial Sloan Kettering Cancer Center\|Shire\|Duke University\|Weill Medical College of Cornell University\|Lehigh Valley Health Network	Leukemia	August 2013	Phase 2
NCT00016302	National Cancer Institute (NCI)	T-cell Childhood Acute Lymphoblastic Leukemia\|Untreated Childhood Acute Lymphoblastic Leukemia	April 2001	Not Applicable
NCT02560025	Massachusetts General Hospital\|Takeda	Acute Myeloid Leukemia	December 2015	Phase 2
NCT00002093	Nexstar Pharmaceuticals\|NIH AIDS Clinical Trials Information Service	Sarcoma, Kaposi\|HIV Infections		Phase 3
NCT00002691	Memorial Sloan Kettering Cancer Center	Lymphoma	August 1995	Phase 2
NCT04920500	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	Acute Myeloid Leukemia	September 4, 2020	Not Applicable
NCT00109837	SWOG Cancer Research Network\|National Cancer Institute (NCI)	Leukemia	April 2005	Phase 2
NCT00130195	Japan Adult Leukemia Study Group	Acute Lymphoblastic Leukemia	September 2002	Phase 2
NCT00002798	National Cancer Institute (NCI)	Childhood Acute Erythroleukemia (M6)\|Childhood Acute Megakaryocytic Leukemia (M7)\|Childhood Acute Monoblastic Leukemia (M5a)\|Childhood Acute Monocytic Leukemia (M5b)\|Childhood Acute Myeloblastic Leukemia With Maturation (M2)\|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)\|Childhood Acute Myelomonocytic Leukemia (M4)\|Childhood Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Refractory Anemia\|Refractory Anemia With Excess Blasts\|Refractory Anemia With Excess Blasts in Transformation\|Refractory Anemia With Ringed Sideroblasts\|Secondary Myelodysplastic Syndromes\|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	August 1996	Phase 3
NCT00002766	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	March 1996	Phase 3
NCT04043494	University Hospital Muenster\|Deutsche Krebshilfe e.V., Bonn (Germany)	Lymphoblastic Lymphoma, Childhood	August 23, 2019	Phase 3
NCT02914977	Tara Lin\|University of Kansas Medical Center	Acute Lymphocytic Leukemia\|Acute Myeloid Leukemia	November 2016	Phase 1
NCT00075725	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|Adult B Acute Lymphoblastic Leukemia\|Childhood B Acute Lymphoblastic Leukemia	December 29, 2003	Phase 3
NCT01238211	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1\|Core Binding Factor Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	December 14, 2010	Phase 2
NCT00002744	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	May 1996	Phase 3
NCT04659616	OHSU Knight Cancer Institute\|Incyte Corporation\|Oregon Health and Science University	Acute Myeloid Leukemia	January 14, 2021	Phase 1
NCT00131027	Japan Adult Leukemia Study Group	Lymphoblastic Leukemia, Acute	September 2002	Phase 3
NCT00363025	Acute Leukemia French Association\|Assistance Publique - Hôpitaux de Paris	Acute Myeloid Leukemia	November 1999	Phase 3
NCT01627041	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Adult Acute Basophilic Leukemia\|Adult Acute Monoblastic Leukemia\|Adult Acute Monocytic Leukemia\|Adult Acute Myeloid Leukemia With Maturation\|Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL\|Adult Acute Myeloid Leukemia Without Maturation\|Adult Acute Myelomonocytic Leukemia\|Alkylating Agent-Related Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia	September 16, 2011	Phase 2
NCT00002756	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	June 1996	Phase 2
NCT00085124	National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	December 2003	Phase 3
NCT00015860	Jonsson Comprehensive Cancer Center\|National Cancer Institute (NCI)	Leukemia	May 2001	Phase 1\|Phase 2
NCT00046930	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)\|Eli Lilly and Company\|Kanisa Pharmaceuticals	Leukemia\|Myelodysplastic Syndromes	September 17, 2002	Phase 3
NCT01540812	PETHEMA Foundation	Acute Lymphoblastic Leukemia	February 2012
NCT03962465	University of Virginia\|Pfizer\|Vanderbilt University\|University of Wisconsin, Madison\|Virginia Commonwealth University	B-cell Acute Lymphoblastic Leukemia	July 22, 2022	Phase 1
NCT05554406	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic+Myeloproliferative Neoplasm\|Acute Myeloid Leukemia With Myelodysplasia-Related Changes\|Therapy-Related Acute Myeloid Leukemia	February 28, 2023	Phase 2
NCT00427414	AIDS Malignancy Consortium\|National Cancer Institute (NCI)\|The Emmes Company, LLC	Sarcoma	September 2008	Phase 1
NCT00004207	University of Leicester\|National Cancer Institute (NCI)	Breast Cancer	December 1997	Phase 1
NCT00840684	Institut Paoli-Calmettes\|National Cancer Institute (NCI)	Leukemia	January 2009	Phase 1\|Phase 2
NCT03164057	St. Jude Children´s Research Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndromes	June 15, 2017	Phase 2
NCT00003783	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	March 1999	Phase 2
NCT03117751	St. Jude Children´s Research Hospital\|Incyte Corporation\|Amgen\|Servier	Acute Lymphoblastic Leukemia\|Acute Lymphoblastic Lymphoma	March 29, 2017	Phase 2\|Phase 3
NCT01806571	Mayo Clinic\|National Cancer Institute (NCI)	Untreated Adult Acute Myeloid Leukemia	March 12, 2015	Phase 2
NCT03007147	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia\|Mixed Phenotype Acute Leukemia\|T Acute Lymphoblastic Leukemia	July 28, 2017	Phase 3
NCT02883049	National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia, BCR-ABL1-Like\|Central Nervous System Leukemia\|Testicular Leukemia	February 27, 2012	Phase 3
NCT04293562	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Myeloid Leukemia	July 20, 2020	Phase 3
NCT02971397	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Acute Myeloid Leukemia	November 2016	Phase 2
NCT05959720	Instituto do Cancer do Estado de São Paulo\|Servier	Acute Lymphoid Leukemia\|Minimal Residual Disease\|Gene Abnormality\|Chemotherapeutic Toxicity	August 2023
NCT00613457	Associazione Italiana Ematologia Oncologia Pediatrica	Leukemia	September 2000	Phase 3
NCT05735184	Kura Oncology, Inc.	Acute Myeloid Leukemia\|Mixed Lineage Acute Leukemia\|Mixed Lineage Leukemia Gene Mutation\|Mixed Phenotype Acute Leukemia\|Refractory AML\|AML With Mutated NPM1\|Acute Myeloid Leukemia Recurrent\|Acute Myeloid Leukemia, in Relapse\|NPM1 Mutation\|KMT2Ar\|Myeloid Sarcoma	July 18, 2023	Phase 1
NCT00372593	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	August 2006	Phase 3
NCT00408005	National Cancer Institute (NCI)	T Acute Lymphoblastic Leukemia\|T Lymphoblastic Lymphoma	January 22, 2007	Phase 3
NCT05939180	The First Affiliated Hospital of Soochow University	Acute Myeloid Leukemia	July 1, 2023	Phase 2\|Phase 3
NCT02582359	Massachusetts General Hospital\|Millennium Pharmaceuticals, Inc.	Acute Myeloid Leukemia	January 2016	Phase 1
NCT04061239	GWT-TUD GmbH	MDS\|AML	August 19, 2019	Phase 2
NCT00618501	Asan Medical Center\|National Cancer Institute (NCI)	Leukemia	October 2005	Phase 2
NCT00004217	SWOG Cancer Research Network\|National Cancer Institute (NCI)	Leukemia	February 2000	Phase 2
NCT00002785	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	July 1996	Phase 2
NCT02472626	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Untreated Adult Acute Myeloid Leukemia	December 2015	Phase 1\|Phase 2
NCT04778397	Gilead Sciences	Acute Myeloid Leukemia	July 1, 2021	Phase 3
NCT02828358	National Cancer Institute (NCI)	Acute Leukemia of Ambiguous Lineage\|B Acute Lymphoblastic Leukemia\|Mixed Phenotype Acute Leukemia	March 27, 2017	Phase 2
NCT02776605	PETHEMA Foundation	ALL	June 2016	Phase 2
NCT02236013	Astellas Pharma Global Development, Inc.\|Astellas Pharma Inc	Acute Myeloid Leukemia	January 7, 2015	Phase 1
NCT00003436	Medical Research Council\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	July 1998	Phase 3
NCT00176462	Rutgers, The State University of New Jersey\|National Cancer Institute (NCI)	Acute Lymphocytic Leukemia	February 2001	Phase 2
NCT03897127	University of Ulm\|Jazz Pharmaceuticals	Acute Myeloid Leukemia	September 4, 2019	Phase 3
NCT02835222	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Untreated Adult Acute Myeloid Leukemia	February 2, 2018	Phase 2
NCT02881086	Goethe University	Acute Lymphoblastic Leukemia\|Lymphoblastic Lymphoma	August 2016	Phase 3
NCT00005863	Medical Research Council\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	August 1998	Phase 3
NCT00066794	SWOG Cancer Research Network\|National Cancer Institute (NCI)	Leukemia	July 2004	Phase 2
NCT00004215	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Anemia\|Leukemia\|Neutropenia\|Thrombocytopenia	August 1999	Phase 2
NCT03135028	Gilead Sciences	Hematologic Malignancy\|Acute Myeloid Leukemia	May 19, 2017	Phase 1
NCT00003728	European Organisation for Research and Treatment of Cancer - EORTC\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	December 1998	Phase 3
NCT00039117	National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	April 2002	Phase 1
NCT03709758	Dana-Farber Cancer Institute\|AbbVie\|Genentech, Inc.	Acute Myeloid Leukemia	October 17, 2018	Phase 1
NCT00002665	SWOG Cancer Research Network\|National Cancer Institute (NCI)	Leukemia\|Neutropenia\|Thrombocytopenia	July 1995	Phase 2
NCT03416179	Pfizer	Leukemia, Myeloid, Acute	April 20, 2018	Phase 3
NCT00101153	University Health Network, Toronto\|National Cancer Institute (NCI)	Leukemia	April 2007	Phase 1
NCT05564390	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	February 28, 2023	Phase 2
NCT03298984	Sumitomo Pharma Oncology, Inc.	Acute Myeloid Leukemia	September 25, 2017	Phase 1
NCT00266136	University Hospital Muenster\|Deutsche Krebshilfe e.V., Bonn (Germany)\|German Federal Ministry of Education and Research	Acute Myeloid Leukemia	June 1999	Phase 3
NCT00070174	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	December 2003	Phase 2
NCT02523976	Institute of Hematology & Blood Diseases Hospital	Acute,Leukemia, Lymphoid	August 1, 2015	Phase 2
NCT01265199	Ascenta Therapeutics\|The Leukemia and Lymphoma Society	Acute Myelogenous Leukemia (AML)	February 2011	Phase 1
NCT02521493	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Down Syndrome\|Myelodysplastic Syndrome\|Myeloid Leukemia Associated With Down Syndrome\|Myeloproliferative Neoplasm	November 23, 2015	Phase 3
NCT04562792	Children´s Mercy Hospital Kansas City	Relapsed Pediatric ALL\|Relapsed Pediatric AML\|Refractory Acute Myeloid Leukemia\|Refractory Acute Lymphoblastic Leukemia	May 8, 2020	Phase 2
NCT00002985	Roswell Park Cancer Institute	Sarcoma	November 1996	Phase 3
NCT00002812	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	September 1996	Phase 3
NCT02036489	PETHEMA Foundation	Acute Lymphobkastic Leukemia	January 2008	Phase 4
NCT00002532	Hannover Medical School\|National Cancer Institute (NCI)	Leukemia	January 1993	Phase 2
NCT00671034	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|Adult B Acute Lymphoblastic Leukemia\|Childhood B Acute Lymphoblastic Leukemia	July 21, 2008	Phase 3
NCT03013998	Beat AML, LLC	Previously Untreated Acute Myeloid Leukemia	November 2016	Phase 1\|Phase 2
NCT01145846	Cooperative Study Group A for Hematology	Acute Myelogenous Leukemia	May 2010	Phase 3
NCT03150693	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia	June 1, 2017	Phase 3
NCT02038777	Pfizer	Acute Myeloid Leukemia	March 25, 2014	Phase 1
NCT01349972	National Cancer Institute (NCI)	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	April 2011	Phase 2
NCT00003423	United Kingdom Children´s Cancer Study Group\|National Cancer Institute (NCI)	Lymphoma	May 1995	Phase 3
NCT00199004	Johann Wolfgang Goethe University Hospital	Adult Acute Lymphocytic Leukemia	April 2004	Phase 4
NCT01324063	European Organisation for Research and Treatment of Cancer - EORTC	Leukemia	November 1986	Phase 3
NCT00006363	National Cancer Institute (NCI)	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Erythroid Leukemia (M6)\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Childhood Acute Basophilic Leukemia\|Childhood Acute Eosinophilic Leukemia\|Childhood Acute Erythroleukemia (M6)\|Childhood Acute Megakaryocytic Leukemia (M7)\|Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)\|Childhood Acute Monoblastic Leukemia (M5a)\|Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)\|Childhood Acute Monocytic Leukemia (M5b)\|Childhood Acute Myeloblastic Leukemia With Maturation (M2)\|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)\|Childhood Acute Myelomonocytic Leukemia (M4)\|Childhood Myelodysplastic Syndromes\|de Novo Myelodysplastic Syndromes\|Untreated Adult Acute Myeloid Leukemia\|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	November 2000	Phase 3
NCT00022737	National Cancer Institute (NCI)	Childhood Acute Lymphoblastic Leukemia in Remission\|Recurrent Childhood Acute Lymphoblastic Leukemia	October 2002	Phase 3
NCT03860844	Sanofi	Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia	August 6, 2019	Phase 2
NCT00005823	Leukemia Research Fund\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	December 1998	Phase 3
NCT02403310	H. Lee Moffitt Cancer Center and Research Institute\|Karyopharm Therapeutics Inc	Leukemia\|Acute Myeloid Leukemia\|AML	June 18, 2015	Phase 1
NCT04214249	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Acute Myeloid Leukemia Post Cytotoxic Therapy\|Secondary Acute Myeloid Leukemia	June 1, 2020	Phase 2
NCT03591510	Novartis Pharmaceuticals\|Novartis	FLT3-mutated Acute Myeloid Leukemia	March 13, 2019	Phase 2
NCT00005793	H. Lee Moffitt Cancer Center and Research Institute\|National Cancer Institute (NCI)\|SmithKline Beecham	Leukemia	July 1999	Phase 1\|Phase 2
NCT00715637	Antisoma Research	Secondary Acute Myeloid Leukemia (Secondary AML, sAML)	June 2007	Phase 3
NCT00526409	PETHEMA Foundation	Acute Lymphoblastic Leukemia	June 2005	Phase 4
NCT02834390	Daiichi Sankyo Co., Ltd.\|Daiichi Sankyo, Inc.	Acute Myeloid Leukemia	August 12, 2016	Phase 1
NCT02198482	University of Ulm	Acute Myeloid Leukemia (AML)\|High-risk Myelodysplastic Syndrome (MDS)	February 2016	Phase 2
NCT00121303	Stichting Hemato-Oncologie voor Volwassenen Nederland	Leukemia\|Myelodysplastic Syndromes	January 2005	Phase 3
NCT02003222	National Cancer Institute (NCI)\|Canadian Cancer Trials Group	Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	December 23, 2013	Phase 3
NCT00002471	Memorial Sloan Kettering Cancer Center	Leukemia\|Lymphoma	February 1990	Phase 2
NCT00136448	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital	Acute Myelogenous Leukemia	February 1993	Phase 2
NCT01228331	Universitätsklinikum Hamburg-Eppendorf	Leukemia	October 2010	Phase 2\|Phase 3
NCT00002925	National Cancer Institute (NCI)	Leukemia	February 1997	Phase 1\|Phase 2
NCT00275106	Children´s Cancer and Leukaemia Group\|European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma\|National Cancer Institute (NCI)	Lymphoma	September 2004	Phase 3
NCT00720109	National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1\|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	July 14, 2008	Phase 2\|Phase 3
NCT02894645	National University Hospital, Singapore	Acute Lymphoblastic Leukemia (ALL)	October 2008	Phase 4
NCT04817241	National Cancer Institute (NCI)	Acute Myeloid Leukemia	February 10, 2022	Phase 1\|Phase 2
NCT00199017	Johann Wolfgang Goethe University Hospital	Lymphoma, Lymphoblastic	April 2004	Phase 4
NCT03836209	PrECOG, LLC.\|Astellas Pharma Inc	Acute Myeloid Leukemia	December 6, 2019	Phase 2
NCT05955261	St. Jude Children´s Research Hospital\|AbbVie	Acute Myeloid Leukemia	July 25, 2023	Phase 2
NCT00369317	Children´s Oncology Group\|National Cancer Institute (NCI)	Childhood Acute Basophilic Leukemia\|Childhood Acute Eosinophilic Leukemia\|Childhood Acute Erythroleukemia (M6)\|Childhood Acute Megakaryocytic Leukemia (M7)\|Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)\|Childhood Acute Monoblastic Leukemia (M5a)\|Childhood Acute Monocytic Leukemia (M5b)\|Childhood Acute Myeloblastic Leukemia With Maturation (M2)\|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)\|Childhood Acute Myelomonocytic Leukemia (M4)\|Childhood Myelodysplastic Syndromes\|de Novo Myelodysplastic Syndromes\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes\|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	March 2007	Phase 3
NCT01546038	Pfizer	Acute Myeloid Leukemia	June 27, 2012	Phase 2
NCT05726110	Shanxi Bethune Hospital\|Antengene Corporation	Relapsed or Refractory Acute Myeloid Leukemia	January 29, 2023	Phase 3
NCT00129168	Kanisa Pharmaceuticals	Leukemia, Myeloid	August 2005	Phase 1\|Phase 2
NCT00186966	Dutch Childhood Oncology Group\|International BFM Study Group\|St. Jude Children´s Research Hospital	Acute Myeloid Leukemia	March 2002	Phase 3
NCT01371981	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Leukemia Cutis\|Myeloid Neoplasm\|Myeloid Sarcoma	June 20, 2011	Phase 3
NCT01451515	St. Jude Children´s Research Hospital\|National University of Singapore	Lymphoblastic Lymphoma	May 25, 2012	Phase 2
NCT00005603	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	March 2000	Phase 3
NCT03900949	Uma Borate\|Ohio State University Comprehensive Cancer Center	Acute Myeloid Leukemia	March 13, 2019	Phase 1
NCT03568994	Baylor College of Medicine\|William Marsh Rice University	Acute Myeloid Leukemia	July 10, 2018	Early Phase 1
NCT00276601	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Leukemia	October 2004	Phase 2
NCT01463046	University of California, San Francisco\|Novartis	Acute Myeloid Leukemia\|Advanced Myelodysplastic Syndrome	January 2012	Phase 1
NCT04440267	wang, jianxiang\|Institute of Hematology & Blood Diseases Hospital	Acute Leukemia of Ambiguous Lineage	June 20, 2020	Phase 2
NCT03286634	National Hospital Organization Nagoya Medical Center	Down Syndrome\|Acute Lymphoblastic Leukemia\|Childhood Cancer	April 18, 2017	Phase 2
NCT03021330	Institute of Hematology & Blood Diseases Hospital	AML	February 8, 2017	Phase 3
NCT01004497	The Catholic University of Korea	Acute Lymphoblastic Leukemia	March 2010	Phase 2
NCT00003700	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Leukemia	January 1999	Phase 2
NCT00195871	Centre Henri Becquerel	Lymphoblastic Lymphoma	February 2004	Phase 2
NCT00003934	National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Promyelocytic Leukemia (M3)\|Childhood Acute Promyelocytic Leukemia (M3)\|Untreated Adult Acute Myeloid Leukemia\|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	June 1999	Phase 3
NCT00343369	Universitätsklinikum Hamburg-Eppendorf\|National Cancer Institute (NCI)	Leukemia	January 2003	Not Applicable
NCT00788892	Jazz Pharmaceuticals	Acute Myeloid Leukemia	October 2008	Phase 2
NCT00187057	St. Jude Children´s Research Hospital\|Children´s Hospital of Philadelphia\|National Cancer Institute (NCI)	Ataxia-Telangiectasia	September 2002	Not Applicable
NCT05157971	City of Hope Medical Center\|National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia\|Ph-Like Acute Lymphoblastic Leukemia	March 17, 2022	Phase 1
NCT02085408	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	February 4, 2011	Phase 3
NCT03850535	Hoffmann-La Roche	Acute Myeloid Leukemia	March 25, 2019	Phase 1\|Phase 2
NCT00004056	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	October 1999	Phase 1
NCT01085617	University College, London	Leukemia\|Mucositis\|Oral Complications	December 2010	Phase 3
NCT01253070	National Cancer Institute (NCI)	Acute Myeloid Leukemia With FLT3+ITD Mutation\|Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11\|Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1\|Acute Promyelocytic Leukemia With PML-RARA\|FLT3 Gene Mutation\|Therapy-Related Acute Myeloid Leukemia	April 1, 2011	Phase 2
NCT00866307	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|Adult B Acute Lymphoblastic Leukemia\|Childhood B Acute Lymphoblastic Leukemia	February 23, 2009	Phase 1
NCT00002700	European Organisation for Research and Treatment of Cancer - EORTC\|Acute Leukemia French Association	Leukemia\|Lymphoma	August 1995	Phase 3
NCT00085709	SWOG Cancer Research Network\|National Cancer Institute (NCI)	Leukemia	July 2004	Phase 3
NCT02326584	Seagen Inc.	Acute Myeloid Leukemia\|Acute Myelogenous Leukemia	December 2014	Phase 1
NCT01477606	University of Ulm\|Novartis Pharmaceuticals	Acute Myeloid Leukemia	May 2012	Phase 2
NCT02323607	Bhavana Bhatnagar\|CTI BioPharma\|Ohio State University Comprehensive Cancer Center	Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	January 12, 2016	Phase 1
NCT00268229	The Cleveland Clinic\|National Cancer Institute (NCI)	Leukemia	July 2003	Phase 1
NCT00526305	PETHEMA Foundation	Acute Lymphoblastic Leukemia	January 2000	Phase 4
NCT02432872	Jianxiang Wang\|Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Acute Myeloid Leukemia	April 2015	Not Applicable
NCT02343939	Gilead Sciences	Acute Myeloid Leukemia	July 1, 2015	Phase 1\|Phase 2
NCT04801797	Massachusetts General Hospital\|AbbVie	Acute Myeloid Leukemia	May 20, 2021	Phase 2
NCT00550992	Dutch Childhood Oncology Group\|BFM Germany\|CORS Monza Italy\|Associazione Italiana Ematologia Oncologia Pediatrica\|Australian and New Zealand Children´s Oncology Group\|BFM Austria\|CLCG France Belgium Portugal\|COALL Germany\|CPH, Czech republic\|DFCI consortium USA\|FRALLE France\|Hong Kong\|MD Anderson USA\|NOPHO Scandinavian countries\|PINDA, Chile\|PPLLSG Poland\|Seattle USA\|SJCRH USA\|UKCCSG United Kingdom	Leukemia	January 2006	Not Applicable
NCT00137111	St. Jude Children´s Research Hospital\|National Cancer Institute (NCI)	Lymphoblastic Leukemia, Acute	July 8, 2000	Phase 3
NCT00023777	SWOG Cancer Research Network\|National Cancer Institute (NCI)	Leukemia	August 2001	Phase 2
NCT03959085	Children´s Oncology Group\|National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia\|B Lymphoblastic Lymphoma\|Central Nervous System Leukemia\|Mixed Phenotype Acute Leukemia\|Testicular Leukemia	October 28, 2019	Phase 3
NCT00199056	Goethe University	Adult Acute Lymphocytic Leukemia	October 1999	Phase 4
NCT00002590	Children´s Oncology Group\|National Cancer Institute (NCI)	Lymphoma	July 1994	Phase 2
NCT02632708	Institut de Recherches Internationales Servier\|Celgene Corporation\|Servier	Newly Diagnosed Acute Myeloid Leukemia (AML)\|Untreated AML\|AML Arising From Myelodysplastic Syndrome (MDS)\|AML Arising From Antecedent Hematologic Disorder (AHD)\|AML Arising After Exposure to Genotoxic Injury	December 31, 2015	Phase 1
NCT00558519	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Leukemia	March 12, 2008	Phase 2
NCT00002704	National Cancer Institute (NCI)	Leukemia	January 1996	Phase 2
NCT00003650	UNICANCER	Lymphoma	February 1997	Phase 3
NCT01156883	Gruppo Italiano Malattie EMatologiche dell´Adulto	Leukemia	April 2010	Not Applicable
NCT02140242	Technische Universität Dresden\|Universitätsklinikum Dresden, Nationales Centrum für Tumorerkrankungen Dresden (NCT+UCC)\|Masaryk University	Leukemia, Myelocytic, Acute	April 16, 2014	Phase 3
NCT00430118	University Hospital Schleswig-Holstein	Leukemia	July 2000	Phase 3
NCT00096135	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	November 2004	Not Applicable
NCT01225874	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	December 1999	Not Applicable
NCT02393859	Amgen	Leukemia, Acute Lymphoblastic	November 10, 2015	Phase 3
NCT02283177	Arog Pharmaceuticals, Inc.	Newly Diagnosed AML With FLT3 Activating Mutations	January 2015	Phase 2
NCT01390337	Daiichi Sankyo, Inc.\|Ambit Biosciences Corporation	Leukemia, Myeloid, Acute	October 2011	Phase 1
NCT02029950	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia-2\|High Risk Myelodysplastic Syndrome\|Myeloproliferative Neoplasm	December 16, 2013	Phase 1
NCT05886049	National Cancer Institute (NCI)	Acute Myeloid Leukemia With KMT2A Rearrangement\|Acute Myeloid Leukemia With NPM1 Mutation	June 30, 2023	Phase 1
NCT00458848	Gruppo Italiano Malattie EMatologiche dell´Adulto	Leukemia	October 2004	Phase 2
NCT00005596	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	April 2000	Phase 3
NCT04326439	Emory University	Acute Myeloid Leukemia\|AML, Childhood	January 24, 2020	Phase 2
NCT00005585	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	April 2000	Phase 3
NCT00004228	Children´s Oncology Group\|National Cancer Institute (NCI)	Lymphoma	June 2000	Phase 3
NCT01802333	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	February 12, 2013	Phase 3
NCT02013648	University of Ulm	Acute Myeloid Leukemia (AML)	July 2014	Phase 3
NCT05453903	Janssen Research & Development, LLC	Leukemia, Myeloid, Acute	October 4, 2022	Phase 1
NCT02419469	M.D. Anderson Cancer Center\|Jazz Pharmaceuticals	Leukemia\|Precursor-B Acute Lymphoblastic Leukemia\|Lymphoblastic Lymphoma\|Lymphoma	November 13, 2015	Phase 2
NCT01256398	National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	December 14, 2010	Phase 2
NCT02303821	Amgen\|Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator\|Innovative Therapies For Children with Cancer Consortium	Acute Lymphoblastic Leukemia (ALL)	February 16, 2015	Phase 1
NCT00198991	Goethe University\|Deutsche Krebshilfe e.V., Bonn (Germany)\|German Federal Ministry of Education and Research	Adult Acute Lymphocytic Leukemia	April 2003	Phase 4
NCT00544999	Institut de Recherche Clinique sur les Cancers et le Sang\|National Cancer Institute (NCI)	Leukemia	September 2007	Phase 1
NCT00187122	St. Jude Children´s Research Hospital	Lymphoblastic Lymphoma	March 1993	Not Applicable
NCT05832320	Peking University People´s Hospital	Acute Promyelocytic Leukemia\|Induction Therapy\|Oral	January 1, 2023	Not Applicable
NCT00005942	National Cancer Institute (NCI)	Chronic Myelomonocytic Leukemia\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia With Excess Blasts\|Refractory Anemia With Excess Blasts in Transformation	March 2000	Phase 1\|Phase 2
NCT00703820	St. Jude Children´s Research Hospital\|Genzyme, a Sanofi Company\|National Cancer Institute (NCI)	Acute Myeloid Leukemia	August 4, 2008	Phase 3
NCT00853008	PETHEMA Foundation	Acute Lymphoblastic Leukemia	January 2003	Phase 4
NCT00003671	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	December 1998	Phase 2
NCT05554393	National Cancer Institute (NCI)	Acute Myeloid Leukemia	February 28, 2023	Phase 2
NCT01890746	Novartis Pharmaceuticals\|Novartis	Acute Leukaemia	September 5, 2013	Phase 2
NCT00002499	Grupo Argentino de Tratamiento de la Leucemia Aguda\|National Cancer Institute (NCI)	Leukemia	January 1990	Phase 2\|Phase 3
NCT00557193	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|Acute Undifferentiated Leukemia\|Childhood T Acute Lymphoblastic Leukemia	January 14, 2008	Phase 3
NCT00866749	M.D. Anderson Cancer Center	Lymphoblastic Leukemia\|Lymphoblastic Lymphoma	September 12, 2006	Phase 2
NCT00002517	European Organisation for Research and Treatment of Cancer - EORTC\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	March 1993	Phase 3
NCT02724163	University of Birmingham\|Assistance Publique - Hôpitaux de Paris\|Cancer Research UK\|National Cancer Institute, France\|Pfizer	Acute Myeloid Leukaemia	April 2016	Phase 3
NCT00005962	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Leukemia	October 4, 2000	Phase 2
NCT00002531	Johann Wolfgang Goethe University Hospital\|National Cancer Institute (NCI)	Leukemia	January 1993	Phase 2
NCT05660473	Institute of Hematology & Blood Diseases Hospital	Precursor Cell Lymphoblastic Leukemia-Lymphoma	October 31, 2022	Phase 2
NCT00651261	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)\|Novartis Pharmaceuticals	Leukemia	April 2008	Phase 3
NCT00850382	University of Ulm	Acute Myeloid Leukemia (AML)	June 2009	Phase 1\|Phase 2
NCT00454480	The University of New South Wales\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	August 2006	Phase 2\|Phase 3
NCT00049517	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Leukemia	December 19, 2002	Phase 3
NCT00002514	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)\|Medical Research Council	Leukemia	May 7, 1993	Phase 3
NCT02112916	National Cancer Institute (NCI)	Adult T Acute Lymphoblastic Leukemia\|Ann Arbor Stage II Adult Lymphoblastic Lymphoma\|Ann Arbor Stage II Childhood Lymphoblastic Lymphoma\|Ann Arbor Stage III Adult Lymphoblastic Lymphoma\|Ann Arbor Stage III Childhood Lymphoblastic Lymphoma\|Ann Arbor Stage IV Adult Lymphoblastic Lymphoma\|Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma\|Childhood T Acute Lymphoblastic Leukemia	September 30, 2014	Phase 3
NCT00093600	Novartis Pharmaceuticals\|Novartis	Acute Myeloid Leukemia (AML)	February 2004	Phase 1
NCT00004128	European Organisation for Research and Treatment of Cancer - EORTC\|Gruppo Italiano Malattie EMatologiche dell´Adulto\|National Cancer Institute (NCI)	Leukemia	September 1999	Phase 3
NCT00814164	Roswell Park Cancer Institute\|Genzyme, a Sanofi Company	Leukemia	December 2008	Phase 2
NCT01773408	Hoffmann-La Roche	Myelogenous Leukemia, Acute	February 2013	Phase 1
NCT00180128	Technische Universität Dresden	Leukemia, Promyelocytic, Acute	January 2000	Phase 4
NCT00111345	University Hospital Muenster\|Deutsche Krebshilfe e.V., Bonn (Germany)	Myeloid Leukemia	March 2004	Phase 2\|Phase 3
NCT05342584	Ioannis Mantzaris\|AbbVie\|Montefiore Medical Center	Acute Myeloid Leukemia\|Myelodysplastic Syndromes	May 25, 2022	Phase 1
NCT03390387	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Childhood Acute Lymphoblastic Leukemia	November 2015	Not Applicable
NCT00002549	European Organisation for Research and Treatment of Cancer - EORTC\|National Cancer Institute (NCI)	Leukemia	November 1993	Phase 3
NCT00124644	Ohio State University Comprehensive Cancer Center\|National Cancer Institute (NCI)	Leukemia	March 2006	Phase 1
NCT02416388	University Hospital, Angers	Acute Myeloid Leukemia (AML)	January 2015	Phase 2\|Phase 3
NCT01117441	University Hospital Schleswig-Holstein\|Deutsche Krebshilfe e.V., Bonn (Germany)	Leukemia	June 2010	Phase 3
NCT00526175	PETHEMA Foundation	Acute Lymphoblastic Leukemia	June 2001	Phase 4
NCT00003593	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	June 1999	Phase 3
NCT00019409	National Institutes of Health Clinical Center (CC)\|National Cancer Institute (NCI)	Leukemia	October 1999	Phase 3
NCT00900445	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|Untreated Childhood Acute Lymphoblastic Leukemia	March 24, 2008
NCT03701308	National Cancer Institute (NCI)	Acute Myeloid Leukemia	January 16, 2019	Phase 2\|Phase 3
NCT01953770	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Childhood Acute Lymphoblastic Leukemia	February 2008	Not Applicable
NCT04174612	Gruppo Italiano Malattie EMatologiche dell´Adulto	Acute Myeloid Leukemia With FLT3+ITD Mutation	April 24, 2020	Phase 3
NCT00018954	National Institutes of Health Clinical Center (CC)\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	October 1992	Phase 2

Molecular Weight

527.52

Formula

C₂₇H₂₉NO₁₀

CAS No.

20830-81-3

SMILES

O=C(C(C(OC)=CC=C1)=C1C2=O)C3=C2C(O)=C(C[C@@](O)(C(C)=O)C[C@@H]4O[C@@]5([H])C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O

Structure Classification

Initial Source

Microorganisms

Streptomyces peucetius and S. peucetius subsp. caesius

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Data Sheet (283 KB) Handling Instructions (2659 KB)

References

[1]. Lehmann M, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7. [Content Brief]

[2]. Dano K, et al. Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. Cancer Res. 1972 Jun;32(6):1307-14. [Content Brief]

[3]. Svensson SP, et al. Melanin inhibits cytotoxic effects of Doxorubicin and Daunorubicin in MOLT 4 cells. Pigment Cell Res. 2003 Aug;16(4):351-4 [Content Brief]

[4]. Gervasoni JE Jr, et al. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and Daunorubicin by induction of both necrosis and apoptosis. Anticancer Res. 2004 Sep-Oct;24(5A):2617-26 [Content Brief]

[5]. Arozal W, et al. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions. Toxicology. 2011 Jan 11;279(1-3):91-9. [Content Brief]

[6]. Emeline Bollaert, et al. MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin. Int J Mol Sci. 2021 May 13;22(10):5153. [Content Brief]

[7]. Cheng Wu, et al. Doxorubicin suppresses chondrocyte differentiation by stimulating ROS production. Eur J Pharm Sci. 2021 Dec 1;167:106013. [Content Brief]

Daunorubicin Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Your Recently Viewed Products:

Daunorubicin

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Daunorubicin (Synonyms: Daunomycin; RP 13057; Rubidomycin)

Other Forms of Daunorubicin:

29 Publications Citing Use of MCE Daunorubicin

View All Topoisomerase Isoform Specific Products:

View All ADC Cytotoxin Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Daunorubicin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report